Recent research indicates that SIGLEC15 is specifically overexpressed in the immunosuppressive microenvironment of glioma and is associated with the polarization of tumor-associated macrophages (TAMs), making it a promising pan-cancer immunotherapeutic target (Wang J. et al., 2023). Here, SIGLEC15 is linked to cancer.